GlassScriptPhysician profile
Christina Acocella
NPI 1487090023
$3,158.46
in general payments reported to CMS, 2019-2025
27 companies · $926 in 2025
The $926 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $734 · 2023: $609 · 2024: $747 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.53 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $367.12 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $312.06 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $276.55 | 2021-2025 | Vraylar, Liletta |
| Exeltis, USA INC. | $226.63 | 2022-2025 | Slynd |
| Coopersurgical, INC. | $211.14 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $206.73 | 2021-2025 | Gardasil 9, Gardasil |
| Sage Therapeutics, LLC | $205.14 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $186.27 | 2021-2022 | |
| Agile Therapeutics, INC. | $157.50 | 2022-2024 | Twirla |
| Millicent US INC | $156.51 | 2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $141.11 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $126.18 | 2022 | |
| Therapeuticsmd, INC. | $97.84 | 2021-2022 | |
| Organon LLC | $89.61 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.54 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $72.06 | 2023-2025 | Cologuard Collection Kit |
| Scynexis, INC. | $36.79 | 2022 | |
| Aspira Women'S Health INC | $34.94 | 2024-2025 | Ova1 |
| Urovant Sciences INC | $23.85 | 2021 | |
| Daiichi Sankyo INC. | $22.13 | 2023 | Injectafer |
| Evofem Biosciences, INC. | $21.11 | 2021 | |
| Boston Scientific Corporation | $20.61 | 2024 | Solyx Sis System |
| Dexcom, INC. | $19.28 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $18.69 | 2025 | Closurefast |
| Conmed Corporation | $18.43 | 2025 | Airseal |
| Supernus Pharmaceuticals, INC. | $15.49 | 2025 | Qelbree |
| Monaghan Medical Corporation | $13.15 | 2023 | Aeroeclipse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Acocella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.